penny stock forum

Related AMTD During A Bullish March, These Were The Stocks That Were Net Buys Among Retail Investors What Success Is Made Of: Investors, Execs And Entrepreneurs Talk Routines And Role Models
Related Investor Movement Index (IMX) for March 2017 Wall Street's M&A Chatter From March 30: Digital Ally, Rio Tinto-Alcoa, NextEra Elliott Management Activist Streak Continues With Demands at BHP Billiton (GuruFocus)

After a another month of record highs for the Dow Jones Industrial Average, which surpassed the $21,000 mark, and the S&P 500, which topped $2,400, TD Ameritrade Holding Corp. (NASDAQ: AMTD) released its March report for the Investor Movement Index. Tracking retail investor movement in and out of equities, the IMX, like the markets at large, hit a new high of 6.22 and showed retail investors were net buyers of equity over the month.

penny stock forum: Intuit Inc.(INTU)

Advisors’ Opinion:

  • [By Asit Sharma]

    It’s tax season — the four months when tax and small-business software providerIntuit Inc.(NASDAQ:INTU) makes most of its profit for the year. On Thursday, Intuit filed its fiscal second-quarter 2017 earnings report and issued a progress report on its tax business so far this year.Tax volumes are well off last year’s pace: Let’s review the details, as well as management’s interpretation, after a look at the headline numbers.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Intuit Inc. (NASDAQ: INTU) which jumped nearly 7% to $137.88. The stocks 52-week range is $101.81 to $140.25. Volume was 4.8 million on the day compared to the average of 1.9 million.

  • [By Shauna O’Brien]

    Morgan Stanley reported on Wednesday that it has downgraded financial management solution provider Intuit Inc. (INTU).

    The firm has cut its rating on INTU to “Underweight,” and has given the company a $62 price target. This price target suggests a 6% decline from the stock’s current price of $66.30. This downgrade reflects the company’s slowing growth of its tax business.

    Intuit shares were mostly flat during pre-market trading Wednesday. The stock is up 11% YTD.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

penny stock forum: T-Mobile US, Inc.(TMUS)

Advisors’ Opinion:

  • [By Daniel Miller]

    As a rule of thumb, the two largest phone carriers in the U.S. have been dominant, followed by a smaller two in Sprint Corporation (NYSE:S) and T-Mobile (NASDAQ:TMUS). With a new administration that might view business deals differently than previous administrations, interest in a merger between Sprint and T-Mobile seems to be heating up. The idea is to create three ultra-competitive phone carriers rather than two dominant and two smaller carriers.

  • [By Chris Lange]

    T-Mobile US, Inc. (NASDAQ: TMUS) reported first quarter financial results after markets closed Monday. The company said that it had $0.80 in diluted GAAP earnings per share (EPS) and $9.61 billion in revenue, versus consensus estimates from Thomson Reuters that called for $0.34 in EPS and $9.62 billion in revenue. The same period from last year had $0.56 in EPS and $8.6 billion in revenue.

  • [By Brian Stoffel]

    But it was the powerhouse wireless division that probably accounted for most of the workforce growth. After all, AT&T is not the only wireless provider tapping the talent pool: Sprint (NYSE:S)made the 13th-most hires last year, and T-Mobile (NASDAQ:TMUS) came in at No. 21.


    Donald Trump’s election has proved a boon for shareholders of Sprint (S) , on the premise that a Republican administration would be open to a merger of the carrier to T-Mobile USA (TMUS) . Regulators under Obama had pushed back against Sprint Chairman Masayoshi Son’s goal of combining the U.S.’s third- and fourth-largest carriers.

penny stock forum: iShares Nasdaq Biotechnology Index Fund(IBB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    One reason for this is the market’s continued ability to leverage what’s working and treat laggards in isolation. Biotechs had led early this year. But as profiled Monday, the iShares Nasdaq Biotech ETF (IBB) had just gotten back to that key resistance line (near 280), which had stunted many similar oversold rallies last year. So, while the pullback isn’t surprising, it is discouraging, especially if it means the IBB could waste the chance of leveraging the longer term bottoming formation.

  • [By Kumar Abhishek]

    Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in a massive underperformance. Gilead stock has underperformedeven the iShares NASDAQ Biotech Index ETF (NASDAQ:IBB) which has returned more than 14% during the same period. Gilead stock has been making lower lows and lower highs going into the earnings, indicating a clear downtrend in the stock. The stock hit its 52 week low of $69.78 recently on January 24th, just days ahead of its Q4 earnings result. Gilead Sciences, Incis scheduled to report its Q4 2016 and FY 2016 earnings on 7th of February, after the market close.

  • [By ]

    After sneaking lower to begin the new trading week, the SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels.

  • [By Ben Levisohn]

    Shares of Gilead Sciences have dipped 0.1% to $68.97 at 1:05 p.m. today, while the iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $296.51.

  • [By Ben Levisohn]

    Shares of Amgen have dropped 0.8% to $146.61 at 2:44 p.m. today, while Regeneron Pharmaceutical has fallen 0.5% to $369.83, and Celgene has gained 2% to $118.10. The iShares Nasdaq Biotechnology ETF (IBB) has risen 0.4% to $269.86.

  • [By Ben Levisohn]

    Biotech stocks have been particularly unloved during the past year, with the iShares Nasdaq Biotech Index ETF (IBB) gaining just 7% to the S&P 500′s 20% rise. Today, however, Amgen (AMGN) is getting a lot of love from the market after releasing Street beating earnings and reporting that its anti-cholesterol drug reduced heart attacks.

penny stock forum: Nabors Industries Ltd.(NBR)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's "Fast Money Halftime Report", Jon Najarian spoke about Nabors Industries Ltd. (NYSE: NBR). He said that somebody bought 6,500 contracts of the July 11 calls for $0.50 in the first half of the session. The trade breaks even at $11.50 or 16.28 percent above the current market price. Jon Najarian has a long position in the name and he is planning to hold it for a month.

  • [By Ben Levisohn]

    Last night, Weatherford International (WFT) reported a smaller than expected loss and announcing an alliance with Nabors Industries (NBR)–and the news was celebrated by the market.

  • [By Craig Jones]

    Pete Najarian was watching Nabors Industries Ltd. (NYSE: NBR). He said that the stock has been trading in a range between $8 and $18 over the last 52 weeks and although it spiked 2.82 percent on Wednesday, it's still close to the lower end of the range. Anticipating a move higher, traders were buying the June 11 calls for $0.30. Around 6,000 contracts were bought in the first half of the session. The trade breaks even at $11.30 or 10.78 percent above the current market price. Pete Najarian decided to buy the calls and he is going to hold them for 4-5 weeks.

Leave a Reply

Your email address will not be published.